Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
139592-37-3
73724-43-3
135273-01-7
1208242-13-0
202751-94-8
1017480-65-7 | 2-(2-Fluorophenyl)morpholine | AA00VSH7 | MFCD09901449
860546-11-8 | 1-amino-4-methylpentan-3-ol | AA00VU0S | MFCD16300694
180718-22-3 | 5H,6H,7H,8H-imidazo[1,5-a]pyridine-7-carboxylic acid hydrochloride | AA00VVAY | MFCD22565914
1000339-13-8 | 2-(2,6-dioxopiperidin-1-yl)ethanesulfonyl chloride | AA0166S6 | MFCD09864173
58-54-8 | Ethacrynic acid | AA0186HY | MFCD00056693
6212-32-4 | 5-(4-chlorophenyl)imidazolidine-2,4-dione | AA018GOH | MFCD03970797
1016702-99-0 | N-(1,3-thiazol-2-yl)piperidine-3-carboxamide | AA018MMZ | MFCD09814263
1314920-48-3 | 2-Methylpyrazolo[1,5-a]pyrazin-4(5H)-one | AA018RQC | MFCD11043953
55967-94-7 | 2-(Oxiran-2-yl)pyridine | AA018RW5 | MFCD11593140
1247165-32-7 | 3-[3-(trifluoromethyl)-1H-pyrazol-1-yl]piperidine | AA018S8H | MFCD16065393